Skip to main content

Table 2 Mean absorbed organ doses from α-RIT with 211At-labeled A11 minibody

From: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

 Mean absorbed dose (Gy/MBq)
OrganWithout NaClO4With NaClO4 c
Blood4.74.8
Bone Marrowa1.31.4
Heart1.51.5
Lungs3.32.4
Salivary glands5.00.9
Throat4.72.1
Thyroidb64.727.5
Stomach5.61.4
Liver1.91.6
Spleen2.81.3
Kidneys2.11.7
Muscle0.30.3
Small intestine1.20.8
Large intestine0.90.6
Bladder2.81.8
Tumor2.21.9
Prostate2.41.5
  1. aDose to bone marrow was estimated using a bone marrow-to-blood-ratio of 0.29
  2. bDose to thyroid was estimated from the throat (assuming that all activity was located in thyroid and using a standard weight of 3 mg)
  3. cDose corresponding to pre-treatment with NaClO4 , using biodistribution data measured at 5 hpi and 9 hpi, complemented with theoretically calculated data for 1, 23 and 42 hpi